Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)
Menopause Jul 15, 2019
Lobo R, et al. - Considering the REPLENISH trial demonstrating significantly improved vasomotor symptoms among women receiving TX-001HR—an oral, softgel capsule, combining 17β-estradiol (E2) and progesterone (E2 mg/P4 mg 1/100, 0.5/100), while having their endometrium protected from hyperplasia, researchers conducted this work defining P4 levels that may be sufficient to counteract the potential endometrial effects of 1 or 0.5 mg oral E2 with TX-001HR. In REPLENISH (phase 3), postmenopausal women treated with TX-001HR (E2 mg/P4 mg: 1/100, 0.5/100, [0.5/50, 0.25/50 and placebo not reported here]) were assessed for serum P4, E2, and estrone (E1) levels, at baseline, week 12, and month 12 for P4, and at baseline, weeks 4 and 12, and months 6, 9, and 12 for E2 and E1. Following 7 daily doses of oral E2 mg/P4 mg (1/100 and 0.5/100), pharmacokinetic parameters were assessed in a phase 1 study. As per findings, the phase 1 and 3 studies were similar regarding P4 levels observed with TX-001HR, and there was no association of the P4 levels with endometrial hyperplasia with either E2 daily dose over 1 year in the REPLENISH phase 3 study, which showed significant improvements in menopausal vasomotor symptoms.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries